Arrowhead Pharmaceuticals (ARWR) – Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Arrowhead Pharmaceuticals (NASDAQ: ARWR):

• 12/17/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at Piper Sandler from $70.00 to $100.00. They now have an “overweight” rating on the stock.
• 12/11/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at Royal Bank Of Canada from $52.00 to $80.00. They now have an “outperform” rating on the stock.
• 12/9/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at Bank of America Corporation from $62.00 to $81.00. They now have a “buy” rating on the stock.
• 12/2/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at HC Wainwright from $80.00 to $85.00. They now have a “buy” rating on the stock.
• 12/1/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at Bank of America Corporation from $42.00 to $62.00. They now have a “buy” rating on the stock.
• 12/1/2025 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
• 11/26/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $45.00 to $48.00. They now have an “equal weight” rating on the stock.
• 11/20/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at The Goldman Sachs Group, Inc. from $27.00 to $48.00. They now have a “neutral” rating on the stock.
• 11/19/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at Royal Bank Of Canada from $45.00 to $52.00. They now have an “outperform” rating on the stock.
• 11/19/2025 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
• 11/19/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at Piper Sandler from $45.00 to $70.00. They now have an “overweight” rating on the stock.
• 11/12/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $29.00 to $45.00. They now have an “equal weight” rating on the stock.

Insider Activity at Arrowhead Pharmaceuticals

In other news, Director Michael S. Perry sold 16,250 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $61.03, for a total transaction of $991,737.50. Following the transaction, the director owned 115,240 shares of the company’s stock, valued at approximately $7,033,097.20. This represents a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Victoria Vakiener sold 10,040 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $67.68, for a total value of $679,507.20. Following the sale, the director directly owned 35,723 shares of the company’s stock, valued at $2,417,732.64. This represents a 21.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 368,736 shares of company stock worth $23,670,228 in the last ninety days. Corporate insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.